Local inhibition of angiogenesis results in an atrophic non-union in a rat osteotomy model

European Cells and Materials

Volumn 22, Issue , 2011, Pages 1-11

  Fassbender, M ^a   Strobel, C ^a   Rauhe, J S ^a   Bergmann, C ^a   Schmidmaier, G ^b   Wildemann, B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Angiogenesis inhibition; Atrophic non union; Bone healing

Indexed keywords

3,5,4' TRIMETHOXYSTILBENE; ARTESUNATE; FUMAGILLIN; POLYLACTIC ACID; SEMAXANIB; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHIC NONUNION; BLOOD VESSEL; BONE RADIOGRAPHY; CALLUS; CELL ACTIVITY; CELL CULTURE; CHORIOALLANTOIS; CONTROLLED STUDY; DISEASE MODEL; EMBRYO; EMBRYO DEATH; FEMALE; FRACTURE HEALING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KIRSCHNER WIRE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; OSTEOBLAST; PSEUDARTHROSIS; RAT; TIBIA OSTEOTOMY;

EID: 79961191194     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v022a01     Document Type: Article

References (48)

1. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ (1992): HMEC-1: establishment of an immortalised human microvascular endothelial cell line. J Invest Dermatol 99: 683-690.
2. Alex D, Leong EC, Zhang ZJ, Yan GT, Cheng SH, Leong CW, Li ZH, Lam KH, Chan SW, Lee SM (2010) Resveratrol derivative, trans-3,5,4'-Trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem 109: 339-346.
3. Beamer B, Hettrich C, Lane J (2009) Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing. HSS J 6: 85-94.
4. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M (2005) Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-Trimethoxystilbene. Mol Pharmacol 67: 1451-1459.
5. Brinker MR, Bailey DE (1997) Fracture healing in tibia fractures with an associated vascular injury. J Trauma 42: 11-19.
6. Brownlow HC, Reed A, Simpson AHRW (2002) The vascularity of atrophic non-unions. Injury 33: 145-150.
7. Calori GM, Phillips M, Jeetle S, Tagliabue L, Giannoudis PV (2008) Classification of non-union: need for a new scoring system? Injury 39: 59-63.
8. Carano RAD, Filvaroff EH (2003) Angiogenesis and bone repair. Drug Discov Today 8: 980-989.
9. Chen H, Zhou H, Wu G, Lou X (2004) Inhibitory effects of Artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 71: 1-9.
10. Dai J, Rabie AB (2007): VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 86: 937-950.
11. Deckers MM, van Bezooijen RL, van der Horst G, Hoogendam J, van Der Bent C, Papapoulos SE, Löwik CW (2002): Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143: 1545-1553.
12. Dell'Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A, Efferth T (2004) Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial Artesunate. Biochem Pharmacol 68: 2359-2366.
13. Dickson KF, Katzman S, Paiement G (1995) The importance of the blood supply in the healing of tibial fractures. Contemp Orthop 30: 489-493.
14. Efferth T, Sauerbrey A, Olbrich A, Gebhard E, Rauch P, Weber HO, Hengstler JG, Halatsch ME (2003) Molecular modes of action of Artesunate in tumor cell lines. Mol Pharmacol 64: 382-394.
15. Einhorn TA (1995) Enhancement of fracture-healing. J Bone Joint Surg Am 77: 940-956.
16. Folkman J (2004) Endogenous angiogenesis inhibitors. APMIS 112: 496-507.
17. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
18. Frémont L (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
19. Giannoudis PV, Einhorn TA, Schmidmaier G, Marsh D (2008) The diamond concept - open questions. Injury 39: 5-8.
20. Hausman MR, Schaffler MB, Majeska RJ (2001) Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 29: 560-564.
21. Hazel SJ (2003) A novel early chorioallantoic membrane assay demonstrates quantitative and qualitative changes caused by antiangiogenic substances. J Lab Clin Med 141: 217-228.
22. Hietaniemi K, Peltonen J, Paavolainen P (1995) An experimental model for non-union in rats.Injury 26: 681-686.
23. Hou L, Mori D, Takase Y, Meihua P, Kai K, Tokunaga O (2009) Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of antiangiogenesis. Pathol Int 59: 448-461.
24. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of Fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557.
25. Kanczler JM, Oreffo ROC (2008) Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15: 100-114.
26. Kanichai M, Ferguson D, Prendergast PJ, Campbell VA (2008) Hypoxia promotes chondrogenesis in rat mesenchymal stem cells: a role for AKT and hypoxiainducible factor (HIF)-lalpha. J Cell Physiol 216: 708-715.
27. Keramaris NC, Calori GM, Nikolaou VS, Schemitsch EH, Giannoudis PV (2008) Fracture vascularity and bone healing: a systematic review of the role of VEGF. Injury 39: 45-57.
28. Klayman DL (1985) Qinghaosu (artemisinin): an antimalarial drug from China. Science 228: 1049-1055.
29. Kratzel C, Bergmann C, Duda G, Greiner S, Schmidmaier G, Wildemann B (2008) Characterization of a rat osteotomy model with impaired healing. BMC Musculoskelet Disord 9: 135.
30. Liu S, Widom J, Kemp CW, Crews CM, Clardy J (1998) Structure of human methionine aminopeptidase-2 complexed with Fumagillin. Science 282: 1324-1327.
31. Lu C, Miclau T, Hu D, Marcucio RS (2007) Ischemia leads to delayed union during fracture healing: a mouse model. J Orthop Res 25: 51-61.
32. Lucke M, Wildemann B, Sadoni S, Surke C, Schiller R, Stemberger A, Raschke M, Haas NP, Schmidmaier G (2005) Systemic versus local application of gentamicin in prophylaxis of implant-related osteomyelitis in a rat model. Bone 36: 770-778.
33. Pauly S, Luttosch F, Morawski M, Haas NP, Schmidmaier G, Wildemann B (2009) Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone 45: 505-511.
34. Reed AA, Joyner CJ, Brownlow HC, Simpson AH (2002): Human atrophic fracture non-unions are not avascular. J Orthop Res 20: 593-599.
35. Reed AAC, Joyner CJ, Isefuku S, Brownlow HC, Simpson AHRW (2003) Vascularity in a new model of atrophic nonunion. J Bone Joint Surg Br 85: 604-610.
36. Robey PG, Termine JD (1985): Human bone cells in vitro. Calcif Tissue Int 37: 453-460.
37. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M (2001) Biodegradable poly(D,L-lactide) coating of implants for continuous release of growth factors. J Biomed Mater Res 58: 449-455.
38. Schmidmaier G, Wildemann B, Melis B, Krummrey G, Einhorn TA, Haas NP, Raschke M (2004) Development and characterization of a standard closed tibial fracture model in the rat. Eur J Trauma 30: 35-42
39. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM (1997) The anti-angiogenic agent Fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099-6103.
40. Sivakumar B, Harry LE, Paleolog EM (2004) Modulating angiogenesis: more vs. less. JAMA 292: 972-977.
41. Triffitt PD, Cieslak CA, Gregg PJ (1993) A quantitative study of the routes of blood flow to the tibial diaphysis after an osteotomy. J Orthop Res 11: 49-57.
42. Tzioupis C, Giannoudis PV (2007) Prevalence of longbone non-unions. Injury 38: 3-9.
43. Wang J, Lou P, Henkin J (2000) Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 77: 465-473.
44. Weber BG (1982) Klassifizierung der Pseudarthrosen nach morphologischen und klinischen Gesichtspunkten (Classification of pseudo-arthroses from a morphological and clinical point of view). Z Orthop 120: 528-531
45. Wildemann B, Bamdad P, Holmer C, Haas NP, Raschke M, Schmidmaier G (2004) Local delivery of growth factors from coated titanium plates increases osteotomy healing in rats. Bone 34: 862-868.
46. Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L (2006) Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In Vitro 20: 154-162.
47. Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, Cirone P, Griesbach HL, Schneider I, Slusarski DC, Holley SA, Crews CM (2006) A chemical and genetic approach to the mode of action of Fumagillin. Chem Biol 13: 1001-1009.
48. Zhou H, Wang W, Wu G, Lee J, Li A (2007) Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells Vascul Pharmacol 47: 131-138.